Evotec SE
EVO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001412558
No open-market purchases or sales by Evotec SE insiders were filed in the last 90 days; 34 institutions reported holding it in 13F filings for Q2 2026, worth $9.07M in total; no superinvestor holds it.
Other share classesEVOTF
13F holders, Q1 2024
Institutional positions in Evotec SE as of Mar 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 20
- −8 vs. Q4 2023
- Shares held
- 4.94M
- −730.0K (−12.9%) vs. Q4 2023
- Total value
- $38.7M
- −$27.8M (−41.8%) vs. Q4 2023
- New holders
- 2
- 7 more added
- Sold out
- 10
- 7 more reduced
Compare with Q4 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting EVO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 34 | $9.07M |
| Q1 2026 | 46 | $20.3M |
| Q4 2025 | 44 | $30.4M |
| Q3 2025 | 37 | $35.9M |
| Q2 2025 | 37 | $40.5M |
| Q1 2025 | 25 | $30.4M |
| Q4 2024 | 26 | $36.9M |
| Q3 2024 | 24 | $29.6M |
| Q2 2024 | 28 | $35.0M |
| Q1 2024 | 20 | $38.7M |
| Q4 2023 | 28 | $66.5M |
| Q3 2023 | 24 | $12.0M |
| Q2 2023 | 20 | $15.4M |
| Q1 2023 | 19 | $14.5M |
| Q4 2022 | 22 | $21.1M |
| Q3 2022 | 22 | $43.5M |
| Q2 2022 | 21 | $57.3M |
| Q1 2022 | 22 | $83.3M |
| Q4 2021 | 20 | $157.3M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2024
Shares, value and share of portfolio for each institution holding Evotec SE; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Bell Investment Advisors, Inc | 69 | $541 | 0.00% | −43−38.4% | Reduced |
| Parallel Advisors, LLC | 70 | $548 | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 149 | $1.00K | 0.00% | 00.0% | Unchanged |
| Clearstead Advisors, LLC | 200 | $1.07K | 0.00% | +10+5.3% | Added |
| Lindbrook Capital, LLC | 304 | $2.38K | 0.00% | +232+322.2% | Added |
| US Bancorp | 576 | $4.51K | 0.00% | −644−52.8% | Reduced |
| Qube Research & Technologies Ltd | 717 | $5.61K | 0.00% | +707+7,070.0% | Added |
| Signaturefd, LLC | 1,048 | $8.21K | 0.00% | +54+5.4% | Added |
| UBS Group AG | 1,766 | $13.8K | 0.00% | −508−22.3% | Reduced |
| Briaud Financial Planning, Inc | 2,160 | $17.0K | 0.01% | +2,160 | New |
| Bank of America Corp | 4,081 | $32.0K | 0.00% | −1,635−28.6% | Reduced |
| Quadrant Capital Group LLC | 6,306 | $49.4K | 0.00% | +4,176+196.1% | Added |
| ADAR1 Capital Management, LLC | 7,700 | $60.3K | 0.02% | +7,700 | New |
| Cetera Investment Advisers | 24,543 | $192.2K | 0.00% | −1,095−4.3% | Reduced |
| BlackRock Inc. | 37,600 | $294.4K | 0.00% | +25,422+208.8% | Added |
| Optiver Holding B.V. | 41,507 | $325.0K | 0.01% | −39,303−48.6% | Reduced |
| DCF Advisers, LLC | 47,797 | $374.3K | 0.23% | 00.0% | Unchanged |
| Millennium Management LLC | 82,815 | $648.4K | 0.00% | −3,570−4.1% | Reduced |
| Morgan Stanley | 87,606 | $686.0K | 0.00% | +43,899+100.4% | Added |
| Mubadala Investment Co PJSC | 4,597,701 | $36.0M | 0.14% | 00.0% | Unchanged |
| Federated Hermes, Inc. | 0 | $0 | 0.00% | −576,933−100.0% | Sold out |
| Zurcher Kantonalbank (Zurich Cantonalbank) | 0 | $0 | 0.00% | −174,266−100.0% | Sold out |
| Old Mission Capital LLC | 0 | $0 | 0.00% | −12,019−100.0% | Sold out |
| FMR LLC | 0 | $0 | 0.00% | −2,990−100.0% | Sold out |
| HHM Wealth Advisors, LLC | 0 | $0 | 0.00% | −450−100.0% | Sold out |
| First Manhattan Co | 0 | $0 | 0.00% | −225−100.0% | Sold out |
| GAMMA Investing LLC | 0 | $0 | 0.00% | −285−100.0% | Sold out |
| Northwestern Mutual Wealth Management Co | 0 | $0 | 0.00% | −158−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −135−100.0% | Sold out |
| Advisor Group Holdings, Inc. | 0 | $0 | 0.00% | −101−100.0% | Sold out |